lenvatinib

Lenvatinib (E7080) is a multi-target receptor tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, KIT, PDGFR, and RET, and has oral activity. Lenvatinib has the strongest inhibitory activity on VEGFR2 and VEGFR3 (IC50=4/5.2 nM). Lenvatinib has strong anti-tumor activity.

Lenvatinib mesylate (E7080 (mesylate)) is an oral and multi-targeted inhibitor of VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, with potent antitumor activities.

O-Demethyl Lenvatinib, a metabolite of Lenvatinib (E7080), is an orally administered, multi-targeted tyrosine kinase inhibitor. It effectively inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, demonstrating significant antitumor activities [1] [2].

O-Demethyl Lenvatinib hydrochloride, a metabolite of Lenvatinib (E7080), is an orally administered multi-targeted tyrosine kinase inhibitor. It targets and inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, demonstrating potent antitumor activities [1] [2].

Lenvatinib impurity 1 is a byproduct associated with Lenvatinib.

Lenvatinib impurity 10 is a useful organic compound for research related to life sciences and the catalog number is T64460.

Lenvatinib-D4 is a deuterated compound of Lenvatinib. Lenvatinib (T0520) has a CAS number of 417716-92-8. Lenvatinib (T0520) is a Kinase Inhibitor. The mechanism of action of lenvatinib is as a Receptor Tyrosine Kinase Inhibitor.

Lenvatinib (Standard) is a reference standard for research and analysis in studies involving Lenvatinib. Lenvatinib (E7080) is a multi-target receptor tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, KIT, PDGFR, and RET, and has oral activity. Lenvatinib has the strongest inhibitory activity on VEGFR2 and VEGFR3 (IC50=4/5.2 nM). Lenvatinib has strong anti-tumor activity.

Lenvatinib-[D5] (Standard) is a reference standard of Lenvatinib-[D5] intended for quantitative analysis, quality control, and related biochemical research applications.

Lenvatinib-D4 (Standard) is a reference standard of Lenvatinib-D4 intended for quantitative analysis, quality control, and related biochemical research applications. Lenvatinib-d4 is a deuterated compound of Lenvatinib. Lenvatinib has a CAS number of 417716-92-8. Lenvatinib is a Kinase Inhibitor. The mechanism of action of lenvatinib is as a Receptor Tyrosine Kinase Inhibitor.

Rulonilimab (SG001) is a fully human IgG4 monoclonal antibody targeting the programmed cell death protein 1 (PD-1). This product specifically binds to the PD-1 receptor on the surface of T cells, blocking its interaction with ligands PD-L1 and PD-L2. This action alleviates the PD-1 pathway-mediated inhibition of T-cell activation, thereby restoring the immune system's ability to eliminate tumor cells. In clinical studies, Rulonilimab is frequently evaluated in combination with multi-kinase inhibitors (such as Lenvatinib) as a first-line therapy for advanced hepatocellular carcinoma (HCC), aiming to enhance anti-tumor efficacy through the synergistic effects of immune checkpoint inhibition and anti-angiogenesis.